QGEN vs TECH: stock comparison and AI forecast
Qiagen N.V. (QGEN) and Bio-Techne Corp (TECH) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
QGEN Qiagen N.V.
- Price
- $50.35 +48.3% · 6M
- Market Cap
- $10.92B
- P/E Ratio
- 35.7x
- Size
- large-cap
- AI Forecast
TECH Bio-Techne Corp
- Price
- $72.67 +32.8% · 6M
- Market Cap
- $11.40B
- P/E Ratio
- 62.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- QGEN and TECH have similar market capitalizations ($10.92B and $11.40B).
- QGEN trades at 35.7 times trailing earnings, TECH at 62.6 times.
- Over the last six months QGEN returned +48.3% and TECH +32.8%.
- QGEN turns 15.6% of its revenue into net income, against 15.0% for TECH.
- QGEN carries 0.66 times debt per unit of equity, against 0.23 times for TECH.
- TECH yields 0.44% in dividends; QGEN pays none.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | QGEN | TECH |
|---|---|---|
| Market Cap | $10.92B | $11.40B |
| P/E Ratio | 35.71x | 62.65x |
| P/B Ratio | 2.89x | 5.41x |
| Dividend Yield | – | 0.44% |
| EPS | $1.41 | $1.16 |
| Book Value/Share | $17.42 | $13.44 |
| Revenue/Share | – | $7.75 |
| FCF/Share | – | $1.68 |
Profitability & Margins
| Metric | QGEN | TECH |
|---|---|---|
| ROE | 8.4% | 8.6% |
| ROA | 5.1% | 7.0% |
| ROIC | 6.5% | 10.4% |
| Gross Margin | 59.8% | 65.8% |
| Operating Margin | 18.4% | 20.7% |
| Net Margin | 15.6% | 15.0% |
| EBT Margin | 19.0% | 19.8% |
| Tax Rate | 18.1% | 24.4% |
Financial Health
| Metric | QGEN | TECH |
|---|---|---|
| Current Ratio | 3.90x | 4.55x |
| Quick Ratio | 3.31x | 3.35x |
| D/E Ratio | 0.66x | 0.23x |
| Financial Leverage | 1.66x | 1.23x |
| Interest Coverage | 15.9x | 28.6x |
| Working Capital | $1.48B | $581M |
Cash Flow
| Metric | QGEN | TECH |
|---|---|---|
| Operating Cash Flow | $626M | $292M |
| Free Cash Flow | – | $263M |
| Capital Spending | – | -$29M |
| OCF Growth YoY | 40.0% | 1.6% |
| FCF Growth YoY | – | 2.6% |
| FCF/Sales | – | 21.7% |
| CapEx/Sales | – | 2.4% |
Operational Efficiency
| Metric | QGEN | TECH |
|---|---|---|
| Asset Turnover | – | 0.47x |
| Receivables Turnover | – | 5.6x |
| Inventory Turnover | 2.7x | 2.1x |
| Fixed Assets Turnover | – | 5.2x |
| Days Sales Outstanding | – | 65 days |
| Days Inventory | 134 days | 172 days |
| Payables Period | 32 days | 23 days |
| Cash Conversion Cycle | – | 213 days |
Income Statement
| Metric | QGEN | TECH |
|---|---|---|
| Total Revenue | – | $1.22B |
| Operating Income | $376M | $252M |
| Net Income | $318M | $182M |
| R&D Expense | $192M | $95M |
| SG&A Expense | $678M | $452M |
| Cost of Goods Sold | $822M | $416M |
Dividend & Shareholder Information
| Metric | QGEN | TECH |
|---|---|---|
| Dividends Per Share | – | $0.32 |
| Payout Ratio | – | 27.6% |
| Shares Outstanding | 217M | 157M |
| Net Income Growth | – | 147.7% |
| EPS Growth | 28.5% | 152.2% |
QGEN vs TECH: stock comparison and AI forecast
Which is bigger, QGEN or TECH?
QGEN and TECH have similar market capitalizations ($10.92B and $11.40B).
Which is cheaper on earnings, QGEN or TECH?
QGEN trades at 35.7 times trailing earnings, TECH at 62.6 times.
Which stock performed better over the last six months, QGEN or TECH?
Over the last six months QGEN returned +48.3% and TECH +32.8%.
Which one does Intratio's AI model rank higher, QGEN or TECH?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.